Aug 31, 2021 02:48 PM IST
Sun Pharma now has the exclusive right to commercialise Winlevi in the US and Canada. Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021, it added.
- Aug 03, 2021 09:22 AM IST
- Aug 03, 2021 08:44 AM IST
- Aug 02, 2021 10:13 AM IST
The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage forms
- Jul 12, 2021 07:56 PM IST
Net Sales are expected to increase by 19.5 percent Y-o-Y (up 6.3 percent Q-o-Q) to Rs 9062.7 crore, according to ICICI Direct.
- Jul 08, 2021 09:17 AM IST
Erez Israeli who took over as chief executive officer of DRL in 2019 sharpened its focus on costs and execution. Its recovery holds a lesson or two for major drug firms
- Jun 13, 2021 01:17 PM IST
The Mumbai-based company, which is strong in various generic therapeutic segments, is eyeing biosimilars to fuel its future growth.
- May 31, 2021 05:38 PM IST
Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 720 in its research report dated May 28, 2021.
- May 31, 2021 12:35 PM IST
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 830 in its research report dated May 28, 2021.
- May 31, 2021 10:53 AM IST
Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well
- May 28, 2021 02:25 PM IST
- May 28, 2021 02:00 PM IST
- May 26, 2021 08:32 AM IST
Shanghvi will, however, continue to be associated with the company's board in his capacity as a non-executive director and chairman, it added.
- May 11, 2021 10:03 AM IST
US drugmaker Eli Lilly and Co. said it has issued royalty-free, non-exclusive voluntary licences to Sun Pharmaceutical Industries to produce its baricitinib drug in India to help combat the second wave of COVID-19 in India.
- Apr 12, 2021 08:40 PM IST
Net Sales are expected to increase by 6.2 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 8,692.6 crore, according to Sharekhan.
- Mar 14, 2021 11:29 AM IST
As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Sun Pharma is recalling Cequa ophthalmic solution, which is used to treat chronic dry eye.
- Feb 11, 2021 05:35 PM IST
The whistle-blower alleged that Sun Pharma and its subsidiary, Sun Pharmaceutical Laboratories, had diverted funds through Aditya Medisales, its sole distributor in India.
- Feb 03, 2021 08:46 PM IST
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 740 in its research report dated January 30, 2021.
- Feb 02, 2021 09:55 AM IST
- Feb 02, 2021 09:11 AM IST
- Feb 01, 2021 07:32 PM IST
Focus on creating health infrastructure in the Budget 2021 is clearly an incrementally structural move which should indirectly benefit all the domestic oriented companies
- Jan 31, 2021 12:42 PM IST
Sun Pharma's India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed
- Jan 29, 2021 02:29 PM IST
The company announced an interim dividend of Rs 5.50 per share.
- Jan 29, 2021 07:33 AM IST
Brokerage firm Motilal Oswal Financial Services expects a 65.7 percent YoY rise in adjusted net profit and a 7.3 percent YoY rise in revenue for the quarter.
- Jan 22, 2021 01:03 PM IST
Net Sales are expected to increase by 7.7 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 8,782.1 crore, according to Yash Securities.